XLRN News and Press, Acceleron Pharma Inc. From 05/13/20

Preclinical research of murine version of sotatercept reveals significant role of key TGF-beta superfamily proteins, including activin and growth differentiation factor ligands, in pulmonary vascular disease; points to therapeutic strategy in pulmonary arterial hypertension (PAH) Accel...

The following slide deck was published by Acceleron Pharma Inc. in conjunction with their 2020 Q1 earnings Read more ...

Biotech Pulse Source: COVID-19 image by Getty Images; edits by PrudentBiotech.com It has taken a pandemic for biotechs to take flight towards their all-time high. One of the first industry groups to recover from the virus-related selloff and be neutral for the year, biotech indexes hav...

Acceleron Pharma Inc. (XLRN) Q1 2020 Earnings Conference Call May 11, 2020 05:00 p.m. ET Company Representatives Habib Dable - Chief Executive Officer Kevin McLaughlin - Chief Financial Officer Dr. Jay Backstrom - Head of Research & Development Sujay Kango - Chief Commerci...

Acceleron Pharma (NASDAQ: XLRN ): Q1 GAAP EPS of -$0.95 misses by $0.09 . More news on: Acceleron Pharma Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- REBLOZYL ® (luspatercept-aamt), a first-in-class erythroid maturation agent, was approved by the U.S. FDA to treat anemia in adults with lower-risk myelodysplastic syndromes (MDS) - - REBLOZYL received positive CHMP opinion for the treatment of adults with transfusion-dependent...

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Monday, May 11, 2020 at 5:00 p.m. EDT to discuss its first quarter 2020 operating and financial results. The webcast will be accessible under "Events & Presentations" in the Investors &am...

The European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to Acceleron Pharma's (NASDAQ: XLRN ) sotatercept for the treatment of patients with pulmonary arterial hypertension. More news on: Acceleron Pharma Inc., Healthcare stocks news, Read more ...

First therapeutic to receive PRIME designation in pulmonary arterial hypertension since the EMA established the program in 2016 PRIME designation comes just three weeks after US FDA granted sotatercept Breakthrough Therapy designation Acceleron Pharma Inc. (Nasdaq: XLRN), a biopha...

The European Medicines Agency's advisory group CHMP has adopted a positive opinion backing approval of Bristol-Myers Squibb (NYSE: BMY ) and development partner Acceleron Pharma's (NASDAQ: XLRN ) Reblozyl (luspatercept) for the treatment of: More news on: Bristol-Myers Squibb Company, Ac...